검색어: oxaliplatin (영어 - 리투아니아어)

oxaliplatin
oksaliplatina

oxaliplatin capecitabine
oksaliplatina

oxaliplatin on day 1
200 mg/m2 v. per 2 val.

placebo or avastin oxaliplatin
kapecitabinas

xeloda in combination with oxaliplatin:
skausmas

oxaliplatin on day 1, every 2 weeks
oksaliplatina 1-mą ciklo dieną kas 2

oxaliplatin on day 1capecitabine oral bid for 2 weeks
oksaliplatina 1-m ciklo dien kapecitabinas gerti 2 k/p 2 savaites (po

fluoropyrimidine/irinotecan or fluoropyrimidine/oxaliplatin based chemotherapy
chemoterapija su fluoropirimidinu/irinotekanu arba fluoropirimidinu/oksaliplatina

sorafenib had no effect on the pharmacokinetics of gemcitabine or oxaliplatin.
gemcitabino ir oksaliplatinos farmakokinetikai sorafenibas takos nedar.

the major study objective was comparison of pfs in the oxaliplatin cohort.
pagrindinis tyrimo tikslas – iblp palyginimas oksaliplatinos kohortoje.

oxaliplatin on day 1, every 3 weeks capecitabine oral twice daily for 2
vartojimo metodasoksaliplatina 1-m ciklo dien kas 2 savaites

safety data for xeloda in combination with oxaliplatin has been obtained from 900 patients.
xeloda derinant su oksaliplatina xeloda ir oksaliplatinos derinio saugumo duomenys buvo gauti gydant 900 pacient.

oxaliplatin on day 1, every 2 weeks leucovorin on days 1 and 2, every 2
5-fluorouracilas ven svirksti is karto, o

capecitabine has also been used in combination with oxaliplatin for the treatment of advanced gastric cancer.
progresuojančiam skrandžio vėžiui gydyti kapecitabinas taip pat buvo vartojamas kartu su oksaliplatina.

in combination with capecitabine and oxaliplatin (xelox) the frequency of severe diarrhoea may be increased.
vartojant kartu su kapecitabinu ir oksaliplatina (xelox), gali padidėti sunkaus viduriavimo dažnis.

xeloda in combination with oxaliplatin:safety data for xeloda in combination with oxaliplatin has been obtained from 900 patients.
skausmasxeloda derinant su oksaliplatina xeloda ir oksaliplatinos derinio saugumo duomenys buvo gauti gydant 900 pacient.

oxaliplatin-based regimens were administered in combination with bevacizumab in 373 patients (30.4%).
oksaliplatina paremtos chemoterapijos metu 373 pacientai (30,4%) kartu vartojo bevacizumabo.

bevacizumab: there was no clinically significant effect of bevacizumab on the pharmacokinetic parameters of capecitabine or its metabolites in the presence of oxaliplatin.
bevacizumabas: kartu vartojami oksaliplatina ir, bevacizumabas kliniškai reikšmingo poveikio kapecitabino ir jo metabolitų farmakokinetikos parametrams neturėjo.

zaltrap was investigated in one main study involving 1,226 adults with metastatic colorectal cancer that had not responded to oxaliplatin-based treatment.
zaltrap buvo tiriamas viename pagrindiniame tyrime, kuriame dalyvavo 1 226 metastazavusiu kolorektaliniu vėžiu sergantys suaugusieji, kurių gydymas oksaliplatinos preparatais buvo neveiksmingas.

the median overall survival was 10.0 months in cisplatin-based regimens and 10.4 months in oxaliplatin- based regimens.
bendro išgyvenimo mediana gydant cisplatinos turinčiais režimais buvo 10 mėnesių ir 10,4 mėnesio, kai gydyta oksaliplatinos turinčiais režimais.